Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ABVX.PA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.20
N/A
-1.55
vs -1.35
Q2.21
N/A
-1.13
vs -1.26
Q4.21
N/A
-1.48
vs -1.55
Q2.22
N/A
-1.76
vs -1.13
Q4.22
N/A
-1.81
vs -1.48
Q2.23
N/A
-1.45
vs -1.76
Q4.23
N/A
-1.91
vs -1.81
Q2.24
N/A
-1.30
vs -1.45
Q4.24
N/A
-1.50
vs -1.91
Q1.25
N/A
-0.77
vs NA
Sales Growth
YoY
Current
Estimates
Q2.21
NA
NA vs NA
Q4.21
-100%
NA vs 14K
Q2.22
NA
2.2M vs NA
Q4.22
NA
2.2M vs NA
Q2.23
+1%
2.2M vs 2.2M
Q4.23
0%
2.2M vs 2.2M
Q2.24
+202%
6.8M vs 2.2M
Q4.24
+78%
4M vs 2.2M
Q1.25
NA
4.6M vs NA
Q2.25
-82%
1.2M vs 6.8M
Return on Equity
QoQ
Q2.21
-696%
-6.96
vs -1.24
Q4.21
-86%
-0.86
vs -6.96
Q2.22
+3930%
39.3
vs -0.86
Q4.22
-2141%
-21.41
vs 39.3
Q2.23
-65%
-0.65
vs -21.41
Q4.23
-49%
-0.49
vs -0.65
Q2.24
-65%
-0.65
vs -0.49
Q4.24
-233%
-2.33
vs -0.65
Institutionnal Ownership
Quote Panel
Key Metrics
Relative Strength
ABVX.PA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
PAR
Unprofitable
Unprofitable
0.05Â ( 0.71%)
Relative Strenght
Volume Buzz
-8%
Earning Acce
No
Dist 52w H.
45%Forecast
54%2025-Revenue
-83%2025-EPS
93%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How ABVX.PA compares to sector?